Scientists working on new liver disease drug

By Cai Wenjun | March 19, 2015, Thursday |

Online Edition

Local researchers are teaming up with expatriate scientists to develop a new drug for chronic liver disease, scientists said today at the Queenstown Molecular Biology Meetings in Shanghai.

Clinical trials will begin next year, they said.

Previous therapeutic agents treating fibrosis can cause side effects like depression.

The new drug candidate acts without causing serious side effects to the brain, said Raymond Stevens, founding director of iHuman Institute under ShanghaiTech University.

Cell signaling, or communication between human cells, is the key to how the body functions. Signaling begins at the cell surface, where a family of protein receptors called G-protein coupled receptors, or GPCR, is involved in 80 percent of cell surface activities in the human body. The receptors control functions such as growth, reproduction, the nervous system and behavior.

About 40 percent of modern medicines target these receptors.

Shanghai is becoming a center of pharmaceutical innovation through international collaboration. Many overseas companies and institutes are cooperating with local facilities to develop new drugs, said Wang Mingwei, director of the Chinese National Compound Library in Shanghai.

Metro drug liver

About Us
|
Terms of Use
|
RSS
|
Privacy Policy
|
Contact Us
|
Shanghai Call Center: 962288
|
Tip-off hotline: 52920043

沪ICP证：沪ICP备05050403号-1
|
互联网新闻信息服务许可证：31120180004
|
网络视听许可证：0909346
|
广播电视节目制作许可证：沪字第354号
|
增值电信业务经营许可证：沪B2-20120012

Scientists working on new liver disease drug

Email this to your friend